Travoprost ocular preservative-free
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Eye drops containing travoprost (preservative-free).
Drugs List
Therapeutic Indications
Uses
Treatment of elevated intraocular pressure in ocular hypertension
Treatment of elevated intraocular pressure in open-angle glaucoma
Treatment of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma.
Treatment of elevated intraocular pressure in paediatric patients aged 2 months to 18 years old with ocular hypertension or paediatric glaucoma.
Dosage
Adults
Instil 1 drop into the affected eye once daily.
Optimal effect is obtained if the dose is administered in the evening.
Children
Children aged 2 months to 18 years
Instil 1 drop into the affected eye once daily.
Optimal effect is obtained if the dose is administered in the evening.
Additional Dosage Information
When substituting another ophthalmic antiglaucoma medicinal product with travoprost, the other medicinal product should be discontinued and travoprost should be started the following day.
Contraindications
Children under 2 months
Breastfeeding
Pregnancy
Precautions and Warnings
Children aged 2 months to 3 years
Females of childbearing potential
Predisposition to iritis
Predisposition to uveitis
Risk factors for cystoid macular oedema
Wearing of contact lenses
Anterior chamber lens
Aphakia
Congenital glaucoma
Inflammatory glaucoma
Narrow angle glaucoma
Neovascular glaucoma
Ocular inflammation
Pigmentary glaucoma
Pseudoexfoliative glaucoma
Pseudophakia with open angle glaucoma
Pseudophakia with torn posterior lens capsule
Advise patient blurred vision may affect ability to drive/operate machinery
Contains macrogolglycerol hydroxystearate
Avoid contact of product with skin
In combined therapy, administer eye products at least five minutes apart
To reduce systemic absorption compress lacrimal sac during administration
Advise patient that some eye changes may be permanent
Female: Ensure adequate contraception during treatment
Advise patient to avoid touching the eye/other surfaces with container tip
Before initiating treatment inform patient of possibility of eyelash growth
Before initiating treatment inform patient of risk of eyelid skin darkening
Before starting treatment inform patient of risk of increased iris pigment
Remove contact lenses before use and re-insert 15 minutes after use
Travoprost may gradually change the iris colour by increasing the number of melanosomes (pigment granules) in melanocytes. Unilateral treatment can result in permanent heterochromia. The long term effects on the melanocytes and any consequences thereof are currently unknown. Changes in iris colour occurs slowly and has been predominantly seen in patients with mixed coloured irises, however, it has also been observed in patients with brown eyes.
Prostaglandins and prostaglandin analogues may be absorbed though the skin. Women who are pregnant or attempting to become pregnant should exercise appropriate precautions to avoid direct exposure to the contents of the bottle. If contact is made, thoroughly cleanse the exposed area immediately.
Pregnancy and Lactation
Pregnancy
Travoprost is contraindicated during pregnancy.
The manufacturer advises that travoprost should not be used during pregnancy unless clearly necessary. Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/newborn child.
Lactation
Travoprost is contraindicated during breastfeeding.
The manufacturer does not recommend the use of travoprost during breastfeeding. It is unknown whether travoprost from eye drops is excreted in human breast milk. Animal studies have shown excretion of travoprost and metabolites in breast milk.
Side Effects
Abdominal pain
Aggravation of existing asthma
Allergic dermatitis
Anterior chamber inflammation
Anterior chamber pigmentation
Anxiety
Arrhythmias
Asthenia
Asthenopia
Asthma
Blepharitis
Blurred vision
Bradycardia
Cataracts
Changes in hair texture
Chest pain
Conjunctival follicles
Conjunctival oedema
Conjunctivitis
Constipation
Contact dermatitis
Corneal erosion
Cough
Decrease in heart rate
Depression
Diarrhoea
Discolouration of hair
Dizziness
Dry eyes
Dry mouth
Dysgeusia
Dysphonia
Dyspnoea
Dysuria
Ectropion
Epistaxis
Erythema
Eye irritation
Eye pain
Eye pruritus
Eyelash changes
Eyelash growth
Eyelid eczema
Eyelid erythema
Eyelid inflammation
Eyelid pruritus
Eyelid sulcus
Gastrointestinal disorder
Hair growth abnormal
Headache
Hyperpigmentation of skin
Hypertension
Hypertrichosis
Hypoaesthesia eye
Hypotension
Increase in prostate specific antigen (PSA)
Increased iris pigmentation
Increased lacrimation
Iridocyclitis
Iritis
Irregular pulse
Keratitis
Lid margin crusting
Macular oedema
Madarosis
Meibomianitis
Musculoskeletal pain
Mydriasis
Nasal congestion
Nasal dryness
Nausea
Ocular discharge
Ocular discomfort
Ocular hyperaemia
Ophthalmic herpes simplex
Oropharyngeal pain
Palpitations
Peptic ulceration
Periorbital oedema
Photophobia
Photopsia
Pruritus
Punctate keratitis
Rash
Reduced visual acuity
Respiratory disorders
Rhinitis
Seasonal allergy
Skin discolouration
Tachycardia
Throat irritation
Tinnitus
Trichiasis
Urinary incontinence
Uveitis
Vertigo
Visual field defects
Visual haloes
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: November 2022
Reference Sources
Summary of Product Characteristics: Visutrax 40micrograms/ml eye drops, solution in single dose container. VISUfarma UK Ltd. Revised December 2021.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.